149 related articles for article (PubMed ID: 38638445)
21. Prognostic impact of the post-treatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy.
Rupp L; Resag A; Potkrajcic V; Warm V; Wehner R; Jöhrens K; Bösmüller H; Eckert F; Schmitz M
Front Immunol; 2023; 14():1185197. PubMed ID: 37261361
[TBL] [Abstract][Full Text] [Related]
22. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
23. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma.
Demicco EG; Farris AB; Baba Y; Agbor-Etang B; Bergethon K; Mandal R; Daives D; Fukuoka J; Shimizu M; Dias-Santagata D; Ogino S; Iafrate AJ; Gaissert HA; Mino-Kenudson M
Mod Pathol; 2011 Sep; 24(9):1177-90. PubMed ID: 21572404
[TBL] [Abstract][Full Text] [Related]
24. Time trends in the incidence of esophageal adenocarcinoma, gastric adenocarcinoma, and superficial esophagogastric junction adenocarcinoma.
Matsuno K; Ishihara R; Ohmori M; Iwagami H; Shichijyo S; Maekawa A; Kanesaka T; Yamamoto S; Takeuchi Y; Higashino K; Uedo N; Matsunaga T; Morishima T; Miyashiro I
J Gastroenterol; 2019 Sep; 54(9):784-791. PubMed ID: 30927083
[TBL] [Abstract][Full Text] [Related]
25. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas.
van Dekken H; Geelen E; Dinjens WN; Wijnhoven BP; Tilanus HW; Tanke HJ; Rosenberg C
Cancer Res; 1999 Feb; 59(3):748-52. PubMed ID: 9973227
[TBL] [Abstract][Full Text] [Related]
26. Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma.
Wu X; Ke X; Ni Y; Kuang L; Zhang F; Lin Y; Lin W; Xiong X; Huang H; Lin X; Zhang H
J Immunol Res; 2020; 2020():8884683. PubMed ID: 33457428
[TBL] [Abstract][Full Text] [Related]
27. Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival.
Karstens KF; Kempski J; Giannou AD; Pelczar P; Steglich B; Steurer S; Freiwald E; Woestemeier A; Konczalla L; Tachezy M; Reeh M; Bockhorn M; Perez D; Mann O; Lohse AW; Roesch T; Izbicki JR; Gagliani N; Huber S
Cancer Immunol Immunother; 2020 Jun; 69(6):1043-1056. PubMed ID: 32100077
[TBL] [Abstract][Full Text] [Related]
28. The prognostic and potentially immunomodulatory role of cartilage oligomeric matrix protein in patients with gastric and esophageal adenocarcinoma.
Papadakos KS; Gorji-Bahri G; Gialeli C; Hedner C; Hagerling C; Svensson MC; Jeremiasen M; Borg D; Fristedt R; Jirström K; Blom AM
Cancer Immunol Immunother; 2024 Apr; 73(5):93. PubMed ID: 38563861
[TBL] [Abstract][Full Text] [Related]
29. Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses.
Imamura Y; Toihata T; Haraguchi I; Ogata Y; Takamatsu M; Kuchiba A; Tanaka N; Gotoh O; Mori S; Nakashima Y; Oki E; Mori M; Oda Y; Taguchi K; Yamamoto M; Morita M; Yoshida N; Baba H; Mine S; Nunobe S; Sano T; Noda T; Watanabe M
Int J Cancer; 2021 Mar; 148(5):1260-1275. PubMed ID: 32997798
[TBL] [Abstract][Full Text] [Related]
30. AI-assisted discovery of an ethnicity-influenced driver of cell transformation in esophageal and gastroesophageal junction adenocarcinomas.
Ghosh P; Campos VJ; Vo DT; Guccione C; Goheen-Holland V; Tindle C; Mazzini GS; He Y; Alexandrov LB; Lippman SM; Gurski RR; Das S; Yadlapati R; Curtius K; Sahoo D
JCI Insight; 2022 Sep; 7(18):. PubMed ID: 36134663
[TBL] [Abstract][Full Text] [Related]
31. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
32. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.
Valkema MJ; Mostert B; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
Updates Surg; 2023 Feb; 75(2):313-323. PubMed ID: 35836094
[TBL] [Abstract][Full Text] [Related]
33. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.
Yoon HH; Shi Q; Sukov WR; Wiktor AE; Khan M; Sattler CA; Grothey A; Wu TT; Diasio RB; Jenkins RB; Sinicrope FA
Clin Cancer Res; 2012 Jan; 18(2):546-54. PubMed ID: 22252257
[TBL] [Abstract][Full Text] [Related]
34. [Correlation between Immune Microenvironment Features and EGFR Mutation Status
in Lung Adenocarcinoma].
Zhu H; Chen P; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Yuan F; Yu X; Sun Q; Ji J; Wang S; Liu T; Xu L
Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):204-216. PubMed ID: 37035883
[TBL] [Abstract][Full Text] [Related]
35. How to classify adenocarcinomas of the esophagogastric junction: as esophageal or gastric cancer?
Gertler R; Stein HJ; Loos M; Langer R; Friess H; Feith M
Am J Surg Pathol; 2011 Oct; 35(10):1512-22. PubMed ID: 21934477
[TBL] [Abstract][Full Text] [Related]
36. Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
Jammula S; Katz-Summercorn AC; Li X; Linossi C; Smyth E; Killcoyne S; Biasci D; Subash VV; Abbas S; Blasko A; Devonshire G; Grantham A; Wronowski F; O'Donovan M; Grehan N; Eldridge MD; Tavaré S; ; Fitzgerald RC
Gastroenterology; 2020 May; 158(6):1682-1697.e1. PubMed ID: 32032585
[TBL] [Abstract][Full Text] [Related]
37. Identical cytokeratin expression pattern CK7+/CK20- in esophageal and cardiac cancer: etiopathological and clinical implications.
Driessen A; Nafteux P; Lerut T; Van Raemdonck D; De Leyn P; Filez L; Penninckx F; Geboes K; Ectors N
Mod Pathol; 2004 Jan; 17(1):49-55. PubMed ID: 14631371
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
39. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa.
von Rahden BH; Kircher S; Kafka M; Stuermer L; Reiber C; Gattenlöhner S; Germer CT; Grimm M
Cancer Biomark; 2010; 7(6):285-94. PubMed ID: 21694467
[TBL] [Abstract][Full Text] [Related]
40. Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma.
Wagener-Ryczek S; Schoemmel M; Kraemer M; Bruns C; Schroeder W; Zander T; Gebauer F; Alakus H; Merkelbach-Bruse S; Buettner R; Loeser H; Thelen M; Schlößer HA; Quaas A
Cancer Immunol Immunother; 2020 Apr; 69(4):523-533. PubMed ID: 31960110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
